Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118407 | 0.93 | CCR5 (0.47) | CCR5MEN1KMT2ADRD2USP30 | |
| SCHEMBL654359 | 0.85 | CCR5 (0.47) | CCR5MEN1KMT2ADRD2 | |
| SCHEMBL30022483 | 0.85 | CCR5 (0.43) | CCR5MEN1KMT2AMKNK1PDE4A | |
| SCHEMBL3466112 | 0.84 | CCR5 (0.48) | CCR5MEN1KMT2APDE4APDE4B | |
| SCHEMBL3466111 | 0.84 | CCR5 (0.48) | CCR5MEN1KMT2APDE4APDE4B | |
| SCHEMBL3467818 | 0.83 | CCR5 (0.42) | CCR5MEN1KMT2AMKNK1PDE4A | |
| SCHEMBL3467820 | 0.83 | CCR5 (0.42) | CCR5MEN1KMT2AMKNK1PDE4A | |
| SCHEMBL1279704 | 0.83 | USP2 (0.45) | CCR5MEN1KMT2AESR2 | |
| SCHEMBL2425248 | 0.83 | RORC (0.44) | CCR5MEN1KMT2ADRD2USP30 | |
| SCHEMBL13345602 | 0.82 | CCR5 (0.51) | CCR5PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-2061461-B1 | 3-AZABICYCLO[4.1.0]HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | EP | disclosed |
| EP-2061461-B1 | 3-AZABICYCLO[4.1.0]HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | EP | disclosed |
| US-20090281135-A1 | 3-AZABICYCLO [4. 1. 0] HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281135-A1 | 3-AZABICYCLO [4. 1. 0] HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281135-A1 | 3-AZABICYCLO [4. 1. 0] HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-2061461-A2 | 3-AZABICYCLO[4.1.0]HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | Glaxo Group Limited (GB) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008031771-A2 | 3-AZABICYCLO [4. 1. 0] HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031771-A2 | 3-AZABICYCLO [4. 1. 0] HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| US-6403612-B2 | UREA CONTAINING COMPOUNDS INHIBIT THE AGGREGATION OF BLOOD PLATELETS; NONTOXIC | MERCK & CO., INC. | 2002-06-11 | — | — | US | disclosed |
| US-20010044454-A1 | Thrombin receptor antagonists | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | disclosed |
| US-5726313-A | Substituted arylaliphatic compounds, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1998-03-10 | — | — | US | disclosed |
| WO-1995026338-A1 | NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281135-A1 | 3-AZABICYCLO [4. 1. 0] HEPTANE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | HTR5A, ADRA2C, SLC6A3 | CCR5 139/4885MEN1 2019/4885KMT2A 4471/4885 |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | CCR5 465/4885MEN1 3479/4885KMT2A 1674/4885 |
| US-20010044454-A1 | Thrombin receptor antagonists | F2R, TBXA2R, PTAFR | CCR5 1022/4885MEN1 2309/4885KMT2A 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.